Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Dec;30(12):3403-3409.
doi: 10.1007/s43032-023-01295-9. Epub 2023 Jul 14.

Tibolone and Breast Tissue: a Review

Stefano Lello #  1 , Anna Capozzi #  2 , Giovanni Scambia  1 , Gianluca Franceschini  3
Affiliations
Review

Tibolone and Breast Tissue: a Review

Stefano Lello et al. Reprod Sci. 2023 Dec.

Abstract

The safety profile of hormone replacement therapy (HRT) on breast is still controversial. Tibolone is an option of treatment for climacteric syndrome of postmenopausal women. Its risk profile on breast is debated. This is an updated narrative review focusing on the impact of tibolone on breast. Particularly, we will report data from major preclinical and clinical studies regarding the effects of the use of this compound on breast tissue and breast density. Moreover, we will analyze and discuss the most relevant findings of the principal studies evaluating the relationship between tibolone and breast cancer risk. Our purpose is making all clinicians who are particularly involved in women's health more aware of the effects of this compound on breast and, thus, more experienced in the management of menopausal symptoms with this drug. According to the available literature, tibolone seems to be characterized by an interesting safety profile on breast tissue.

Keywords: Breast; Breast cancer; Breast density; Hormone replacement therapy; Menopause; Tibolone.

PubMed Disclaimer

References

    1. Rossouw JE, Anderson GL, Prentice RL, AZ LC, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J, Writing Group for the Women’s Health Initiative Investigators.; Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–33. https://doi.org/10.1001/jama.288.3.321 . - DOI - PubMed
    1. The NAMS. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 2017;24(7):728–53. - DOI
    1. Kloosterboer HJ. Tissue-selective effects of tibolone on the breast. Maturitas. 2004;49(1):S5–S15. https://doi.org/10.1016/j.maturitas.2004.06.022 . - DOI - PubMed
    1. Kloosterboer HJ, Schoonen WG, Deckers GH, Klijn JG. Effects of progestagens and Org OD14 in in vitro and in vivo tumor models. J Steroid Biochem Mol Biol. 1994;49(4-6):311–8. https://doi.org/10.1016/0960-0760(94)90273-9 . - DOI - PubMed
    1. Gompel A, Chaouat M, Jacob D, Perrot JY, Kloosterboer HJ, Rostene W. In vitro studies of tibolone in breast cells. Fertil Steril. 2002;78(2):351–9. https://doi.org/10.1016/s0015-0282(02)03203-x . - DOI - PubMed

MeSH terms

LinkOut - more resources